Advaxis, Inc. Completes $9.4 Million Equity Financing
Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer Study Released
Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
More News
Advaxis is a biotechnology company that uses live genetically modified Listeria monocytogenes to treat cancers, infectious disease and problems of the immune system.